Meetings with the pharmaceutical industry since March 1st 2020
Dear European External Action Service,
Under the right of access to documents in the EU treaties, as developed in Regulation 1049/2001, I am requesting documents which contain the following information:
- all reports (and other notes) from meetings between EEAS and representatives of the pharmaceutical industry (companies as well as organisations such as EFPIA) from March 1st 2020 onwards. This should include the following companies: Bayer AG, Novartis International AG, Merck, GlaxoSmithKline, Amgen Inc, F. Hoffmann-La Roche Ltd, Johnson & Johnson, SANOFI, Pfizer Inc., AstraZeneca, Eli Lilly and Company, and MSD (Europe) Inc. (Merck Sharp & Dohme).
- all correspondence (including emails) between the EEAS and representatives of the pharmaceutical industry (companies as well as organisations such as EFPIA) from March 1st 2020 onwards.
- a list of all the above-mentioned documents (including dates, names of participants/senders/recipients and their affiliation, subject of meeting/correspondence)
Dr. Astrid Viciano
Dear Ms Viciano,
This message is an acknowledgement of receipt for your request for access
to documents under Regulation 1049/2001 regarding public access to
European Parliament, Council and Commission documents (which the EEAS is
Your requests for access to document have been registered under reference
Please refer to this number in any further correspondence.
In accordance with the Regulation, you will receive a reply within 15
working days: 11/12/2020.
EEAS ACCESS TO DOCUMENTS (AD)
[EEAS request email]
SG.AFFGEN.2 – Parliamentary Affairs
1. mailto:[EEAS request email]